While baseline frequencies of CD3‒CD56+ NK cells were not associated with outcome in 61 patients with advanced and/or metastatic HCC treated with αPD‐(L)1 inhibitors, changes in NK‐cell frequencies after treatment were independent prognostic factors for survival, with higher levels of CD3‒CD56+ NK cells positively associating with prolonged PFS and OS.72 The gene discussed is NCAM1; the disease is hepatocellular carcinoma.